Clinical Practice: The role of biosimilar granulocyte colony stimulating factor (GCSF) Zarzio for progenitor cell mobilization and the treatment of therapy-induced neutropenia in adult hematopoietic stem cell transplantation

Cherie Severson

Abstract


Originator GCSF (Neupogen) has been used to mobilize progenitor stem cells and treat therapy-induced neutropenia in Canadian stem cell transplant settings for years. Although its benefit is not in question, viable alternatives are available. Biosimilar GCSF (Zarzio) is widely in use in Europe since 2009 and was recently approved in the U.S. for the same five indications as Neupogen. Zarzio is reported as safe, equally efficacious, more accessible and cost effective without negatively impacting patient outcomes. This paper summarizes the supporting evidence. 

Key words: biosimilar GCSF, Zarzio, autologous transplant, mobilization, neutropenia, cost


Full Text:

PDF

References


Aapro, M., Cornes, P., & Abraham, I. (2011). Comparative cost-efficiency across the European G5 countries of various regimens of filgrastim, biosimilar filgrastim and peg filgrastim to reduce the incidence of chemotherapy-induced febrile neutropenia. Journal of Oncology Pharmacy Practice, 18(2), 171–179.

Bassi, S., Stroppa, E.M., Moroni, C.F., Arbasi, M.C., Trabacchi, E., Di Franco, A., Lazzaro, A., … Valissa, D. (2015). Safety and efficacy of granulocyte colony-stimulating factor biosimilars in engraftment after autologous stem cell transplantation for hematological malignancies: A 4-year, single institute experience with different conditioning regimens. Blood Transfusion, 13, 478–483. doi:10.2450/2015.0198-14

Bonig, H., Becker, P.S., Schwebig, A., & Turner, M. (2015). Biosimilar granulocyte colon stimulating factor for healthy donor stem cell mobilization: Need we be afraid? Transfusion, 55, 430–439.

Canadian Cancer Society’s Advisory Committee (2015). Canadian cancer statistics 2015 special topic: Predictions of the future burden of cancer in Canada. 1–151. Toronto, ON: Author. Retrieved from http://www.cancer.ca/statistics

Gascon, P. (2012). Presently available biosimilars in hematology-oncology: GCSF. Target Oncology, 7(Suppl. 1), S29–S34. doi:10.1007/s11523-011-0190-9

Gascon, P., Tesch, H., Verpoort, K., Rosati, M.S., Salesi, N., Agrawal, S., Wilking, N., … Turner, M. (2013). Clinical experience with Zarzio in Europe: What have we learned? Support Care Cancer, 21, 2925–2932.

Hamburg, M. (2015). FDA approves Zarzio as first US biosimilar. Retrieved from http://www.onclive.com/web-exclusives/FDA-Approves-Zarziowas-as-First-Biosimilar

Ianotto, J.C., Sack, F.N., Couturier, M.A., Tempescul, A., Mugnier, N., Delepine, P., Guillerm, G., & Berthou, C. (2014). Biosimilars of filgrastim in autologous stem cell transplant: Reduction in granulocyte-colony stimulating factor costs, but similar effects on bone marrow recovery. Leukemia and Lymphoma, 55, 74–77.

Ianotto, J.C., Tempescul, A., Yan, X., Delepine, P., Le Calloch, R., Hardy, E., Eveillard, J.R., … Guillerm, G. (2012). Experience (1 year) of GCSF biosimilars in PBSCT for lymphoma and myeloma patients. (Letter to the editor). Bone Marrow Transplantation, 47, 874–876.

Lefrere, F., Brignier, A.C., Elie, C., Ribeil, J.A., Bernimoulin, M., Aoun, C., Cortivo, L.D., … Cavazzana-Calvo, M. (2011). First experience of autologous peripheral blood stem cell mobilization with biosimilar granulocyte colony-stimulating factor. Advances in Therapeutics, 28(4), 304–310.

McBride, D. (2015). First biosimilar drug approval paves way for cheaper cancer treatments. ONS Connect. Retrieved from htpp://www.connect.ons.org

Remenyi, P., Gopsca, L., Marton, I., Reti, M., Mikala, G., Peto, M., Barta, A., … Masszi, T. (2014). Peripheral blood stem cell mobilization and engraftment after autologous stem cell transplantation with biosimilar rhG-CSF. Advances in Therapy, 31, 451–460.

Schmitt, M., Publicover, A., Orchard, K.H., Matthias, G., Wang, L., Schmitt, A., Mani, J., … Nagler, A. (2014). Biosimilar GCSF based mobilization of peripheral blood hematopoietic stem cell transplantation. Theranostics, 4(3), 280–289.

Scottish Medicines Consortium. (2011). Providing advice about the status of all newly licensed medicines. Retrieved from www.scotishmedicines.org.uk

Turner & Associates. (2008). Issues of access to cancer drugs in Canada: A report for the Canadian cancer action network. 1–91. Retrieved from www.ccanceraction.ca/wp-content/upload/2014/11/3-CCAN-Pharma-Report-Final-PDF.pdf

United States Food and Drug Administration. (2015). Zarzio: Highlights of prescribing information. Retrieved from www.accessdata.fda.gov/drugsatfda_docs/label/2015/1255531lbl.pdf

Verpoort, K., & Mohler, T.M. (2012). A non-interventional study of biosimilar granulocyte colony-stimulating factor as prophylaxis for chemotherapy-induced neutropenia in a community oncology centre. Therapeutic Advances in Medical Oncology, 4(6), 289–293.


Refbacks

  • There are currently no refbacks.


Bookmark and Share